EDMONTON, ALBERTA (April 20, 2022) – GlycoNet, one of many world’s leaders in glycomics analysis and discovery, introduced a $1.73 million funding for 13 glycomics tasks throughout Canada. Business collaborators, well being foundations and enterprise companions are additionally co-investing $5.97 million, bringing the whole funding to $7.7 million. This funding will assist analysis crucial to enhancing the standard of life for sufferers with continual illnesses, most cancers, infectious illnesses and neurodegenerative illnesses.
“Canada’s management in glycomics—the research of carbohydrates—is now driving our work in new diagnostics, therapeutics, applied sciences and vaccines,” says Elizabeth Nanak, CEO, GlycoNet. “Our funding will additional develop home analysis, commercialization and assist practice extremely expert personnel—an important a part of constructing a sustainable, knowledge-based bioeconomy.”
One of many funded initiatives is a Phase I clinical trial investigating the safety of a natural, carbohydrate-based product to slow the breakdown of starch in people with sort 2 diabetes. This drug candidate, developed by Stephen Withers, Robert Petrella, J.P. Heale and Joerg Bohlmann from the College of British Columbia, is anticipated to have fewer unwanted effects than different medication of this normal class at the moment out there to sufferers with sort 2 diabetes.
Additional, this funding will assist a undertaking set to develop immune-based protecting therapeutics for Alzheimer’s illness, the most typical explanation for dementia that afflicts greater than 400,000 Canadians over the age of 65. The staff led by Matthew Macauley on the College of Alberta is learning how a carbohydrate-binding protein in the brain can potentially provide protective effects towards the illness.
“We’ve been making thrilling advances in understanding the function of carbohydrates within the mind and the way they have an effect on immune cell operate,” says Macauley. “Because of the assist from GlycoNet and our different companions, we’re now creating a possible therapeutic technique to decelerate the development of Alzheimer’s illness.”
This funding can also be funding preclinical trials of a carbohydrate-derived drug to deal with Duchenne muscular dystrophy. The staff together with Sachiko Sato, Masahiko Sato, and Jérôme Frenette at Université Laval is learning how this drug could reduce tissue damage by as much as 50 per cent and doubtlessly be used to deal with different forms of muscular dystrophies as properly.
This funding additionally strengthens Canadian collaboration with the glycomics communities in Asia and all through North America. A world analysis staff led by Ching-Ching Yu (Nationwide Chung Cheng College), Chun-Hung Lin (Academia Sinica) and David Kwan (Concordia College) is creating a expertise to analyze interactions between carbohydrates and carbohydrate-binding proteins, which play a crucial function in irritation and cell well being and will result in new avenues for drug improvement.
By way of mobilizing data and experience within the research of carbohydrates, together with strategic investments and partnerships, this funding will allow researchers to develop made-in-Canada options to unmet well being points, leading to new firms, jobs and a optimistic financial influence.
- Glycomics is the research of glycans (carbohydrates or sugars) in all residing organisms.
- Right this moment’s announcement is for $1.73 million in funding for glycomics analysis and an extra $5.97 million in co-funding from analysis companions and trade collaborators throughout Canada.
- The awarded tasks fall below 4 of GlycoNet’s funding streams—strategic initiatives, translational grants, worldwide partnerships and scientific partnerships. This funding will assist eight tasks inside GlycoNet’s Strategic Initiatives Grant, two Translational Grants, two Scientific Partnerships Grants and one Worldwide Partnerships Grant.
- Since 2015, GlycoNet has invested $29 million from the federal Community of Centres of Excellence program and leveraged $35 million of associate funding into R&D, skilled over 550 extremely certified personnel and has supported the start-up of 5 new Canadian firms.
Be taught extra here in regards to the tasks receiving funding.
GlycoNet is advancing analysis, innovation and coaching in glycomics to enhance the standard of lifetime of Canadians. GlycoNet is a one-stop international vacation spot targeted on creating new carbohydrate-based medication, vaccines and diagnostics, in collaboration with educational and trade organizations to deal with areas of unmet want by utilized glycomics analysis. Funded by the federal Networks of Centres of Excellence (NCE) program and a spread of companions, the community consists of over 175 researchers throughout Canada who deal with most cancers, continual illnesses, infectious illnesses and neurodegenerative illnesses. This nationwide platform helps translational analysis, safety of mental property, novel drug improvement, firm formation and coaching. Be taught extra about us at glyconet.ca.
Communications Affiliate, GlycoNet
Senior Account Supervisor, PR Associates
Disclaimer: AAAS and EurekAlert! should not liable for the accuracy of reports releases posted to EurekAlert! by contributing establishments or for using any data by the EurekAlert system.